98%
921
2 minutes
20
Aims: Anti-tachycardia pacing (ATP) is a reliable electrotherapy to painlessly terminate ventricular tachycardia (VT). However, ATP is often ineffective, particularly for fast VTs. The efficacy may be enhanced by optimized delivery closer to the re-entrant circuit driving the VT. This study aims to compare ATP efficacy for different delivery locations with respect to the re-entrant circuit, and further optimize ATP by minimizing failure through re-initiation.
Methods And Results: Seventy-three sustained VTs were induced in a cohort of seven infarcted porcine ventricular computational models, largely dominated by a single re-entrant pathway. The efficacy of burst ATP delivered from three locations proximal to the re-entrant circuit (septum) and three distal locations (lateral/posterior left ventricle) was compared. Re-initiation episodes were used to develop an algorithm utilizing correlations between successive sensed electrogram morphologies to automatically truncate ATP pulse delivery. Anti-tachycardia pacing was more efficacious at terminating slow compared with fast VTs (65 vs. 46%, P = 0.000039). A separate analysis of slow VTs showed that the efficacy was significantly higher when delivered from distal compared with proximal locations (distal 72%, proximal 59%), being reversed for fast VTs (distal 41%, proximal 51%). Application of our early termination detection algorithm (ETDA) accurately detected VT termination in 79% of re-initiated cases, improving the overall efficacy for proximal delivery with delivery inside the critical isthmus (CI) itself being overall most effective.
Conclusion: Anti-tachycardia pacing delivery proximal to the re-entrant circuit is more effective at terminating fast VTs, but less so slow VTs, due to frequent re-initiation. Attenuating re-initiation, through ETDA, increases the efficacy of delivery within the CI for all VTs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935023 | PMC |
http://dx.doi.org/10.1093/europace/euac165 | DOI Listing |
Background: Anti-tachycardia pacing (ATP) delivered from implantable cardioverter defibrillators (ICDs) provides critically timed pacing pulses to terminate ventricular tachycardia (VT). Physiological pacing through left bundle branch area (LBBA) pacing has emerged as a clinically relevant alternative to induce synchronous activation of the ventricles. The main objective of this study was to compare the efficacy and safety of ATP delivered to an LBBA lead and a conventional RV lead.
View Article and Find Full Text PDFEur Heart J Case Rep
August 2025
Department of Cardiovascular Medicine, University of Oxford, Wellington Square, Oxford OX1 2JD, UK.
Background: Implantable cardioverter-defibrillators (ICDs) prevent sudden cardiac death due to ventricular arrhythmia. A novel extravascular ICD (EV-ICD) system provides improved functionality over previous transvenous (TV-ICD) and subcutaneous (S-ICD) alternatives, particularly in younger patients. This includes limited bradycardia pacing, anti-tachycardia pacing therapy, and lower energy defibrillation, all within a smaller device profile compared to the S-ICD.
View Article and Find Full Text PDFRadiother Oncol
August 2025
Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Introduction: We present the first-in-human application of stereotactic radiosurgery (SRS) targeting the left stellate ganglion (LSG) as a non-invasive neuromodulatory strategy for treating polymorphic ventricular tachycardia/ventricular fibrillation (VT/VF).
Materials And Methods: A 69-year-old man with mixed-etiology cardiomyopathy (LVEF 28 %) experienced 27 VT/VF episodes over three months. This resulted in 18 implantable cardioverter-defibrillator (ICD) shocks and nine anti-tachycardia pacing therapies, despite optimal pharmacotherapy, catheter ablation and two temporary LSG blocks.
Eur Heart J Case Rep
July 2025
Department of Electrophysiology, AZ Sint-Jan Hospital, Ruddershove 10, Bruges B-8000, Belgium.
Background: Extra-vascular implantable cardioverter defibrillator (EV-ICD) is an emerging technique for ICD implantation with substernal lead placement. The system avoids the vasculature and can deliver anti-tachycardia and pause prevention pacing, with a generator size smaller than the existing subcutaneous device. While this device is now widely available, little is known about potential complications that may follow its implantation in real life context.
View Article and Find Full Text PDFHeartRhythm Case Rep
May 2025
Montreal Heart Institute, Department of Medicine, Université de Montréal, Montreal, Quebec, Canada.